Khalid M. Alhusayni, Abdulmajeed M. Aljuaid, Abdulaziz M. Alkhammash, Shahad A. Alzahrani, Abeer K. Alorabi, Yasmin B. Alotaibi, Nidaa T. Alhumaidi, Waad K. Alharbi, Ghaliah A. Harbi, Ibrahim Alzahrani
{"title":"胰高血糖素样肽-1受体激动剂药物的安全性和有效性:综合文献综述","authors":"Khalid M. Alhusayni, Abdulmajeed M. Aljuaid, Abdulaziz M. Alkhammash, Shahad A. Alzahrani, Abeer K. Alorabi, Yasmin B. Alotaibi, Nidaa T. Alhumaidi, Waad K. Alharbi, Ghaliah A. Harbi, Ibrahim Alzahrani","doi":"10.3889/oamjms.2023.11735","DOIUrl":null,"url":null,"abstract":"There is a new class of antihyperglycemic medications called glucagon-like peptide-1 receptor agonists (GLP-1RAs). They work by increasing the effects of insulin on peripheral tissues, decreasing the liver’s glucose production, improving satiety through central nervous system action, as well as encouraging appropriate pancreatic cell production and (glucagon) suppression. GLP-1 agonists are a group of drugs used to manage type 2 diabetes mellitus and promote weight reduction. However, they cause several unfavorable side effects such as diarrhea, constipation, nausea, and vomiting, as expected. After extensive research, several clinical studies have found them to be safe for the heart and kidneys. Moreover, patients with a history of pancreatitis are advised to avoid GLP-1RA-based treatments, even though there is insufficient information to determine whether there is a causal relationship.","PeriodicalId":19562,"journal":{"name":"Open Access Macedonian Journal of Medical Sciences","volume":"217 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonist Drugs: A Comprehensive Literature Review\",\"authors\":\"Khalid M. Alhusayni, Abdulmajeed M. Aljuaid, Abdulaziz M. Alkhammash, Shahad A. Alzahrani, Abeer K. Alorabi, Yasmin B. Alotaibi, Nidaa T. Alhumaidi, Waad K. Alharbi, Ghaliah A. Harbi, Ibrahim Alzahrani\",\"doi\":\"10.3889/oamjms.2023.11735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is a new class of antihyperglycemic medications called glucagon-like peptide-1 receptor agonists (GLP-1RAs). They work by increasing the effects of insulin on peripheral tissues, decreasing the liver’s glucose production, improving satiety through central nervous system action, as well as encouraging appropriate pancreatic cell production and (glucagon) suppression. GLP-1 agonists are a group of drugs used to manage type 2 diabetes mellitus and promote weight reduction. However, they cause several unfavorable side effects such as diarrhea, constipation, nausea, and vomiting, as expected. After extensive research, several clinical studies have found them to be safe for the heart and kidneys. Moreover, patients with a history of pancreatitis are advised to avoid GLP-1RA-based treatments, even though there is insufficient information to determine whether there is a causal relationship.\",\"PeriodicalId\":19562,\"journal\":{\"name\":\"Open Access Macedonian Journal of Medical Sciences\",\"volume\":\"217 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Access Macedonian Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3889/oamjms.2023.11735\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Macedonian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3889/oamjms.2023.11735","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonist Drugs: A Comprehensive Literature Review
There is a new class of antihyperglycemic medications called glucagon-like peptide-1 receptor agonists (GLP-1RAs). They work by increasing the effects of insulin on peripheral tissues, decreasing the liver’s glucose production, improving satiety through central nervous system action, as well as encouraging appropriate pancreatic cell production and (glucagon) suppression. GLP-1 agonists are a group of drugs used to manage type 2 diabetes mellitus and promote weight reduction. However, they cause several unfavorable side effects such as diarrhea, constipation, nausea, and vomiting, as expected. After extensive research, several clinical studies have found them to be safe for the heart and kidneys. Moreover, patients with a history of pancreatitis are advised to avoid GLP-1RA-based treatments, even though there is insufficient information to determine whether there is a causal relationship.
期刊介绍:
Open Access Macedonian Journal of Medical Sciences (OAMJMS) [formerly known as Macedonian Journal of Medical Sciences] is a top-tier open access medical science journal published by the ID Design 2012/DOOEL Skopje, Rajko Zhinzifov No 48, 1000 Skopje, Republic of Macedonia. OAMJMS is an international, modern, general medical journal covering all areas in the medical sciences, from basic studies to large clinical trials and cost-effectiveness analyses. We publish mostly human studies that substantially enhance our understanding of disease epidemiology, etiology, and physiology; the development of prognostic and diagnostic technologies; trials that test the efficacy of specific interventions and those that compare different treatments; and systematic reviews. We aim to promote translation of basic research into clinical investigation, and of clinical evidence into practice. We publish occasional studies in animal models when they report outstanding research findings that are highly clinically relevant. Our audience is the international medical community as well as educators, policy makers, patient advocacy groups, and interested members of the public around the world. OAMJMS is published quarterly online version. The Open Access Macedonian Journal of Medical Sciences (OAMJMS) publishes Medical Informatics, Basic Science, Clinical Science, Case Report, Brief Communication, Public Health, Public Policy, and Review Article from all fields of medicine and related fields. This journal also publishes, continuously or occasionally, the bibliographies of the members of the Society, medical history, medical publications, thesis abstracts, book reviews, reports on meetings, information on future meetings, important events and dates, and various headings which contribute to the development of the corresponding scientific field.